$LAB
STANDARD BIOTOOLS INC.

2024 Q3 Form 10-Q Financial Statement

#000095017024091888 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $44.97M $37.21M $27.67M
YoY Change 77.27% 34.48% 47.34%
Cost Of Revenue $21.71M $22.30M $14.06M
YoY Change 52.73% 58.54% -1.99%
Gross Profit $23.26M $14.91M $13.60M
YoY Change 108.54% 9.6% 207.25%
Gross Profit Margin 51.73% 40.07% 49.17%
Selling, General & Admin $34.40M $37.67M $22.60M
YoY Change 54.33% 66.7% -25.62%
% of Gross Profit 147.9% 252.71% 166.15%
Research & Development $13.16M $19.22M $6.184M
YoY Change 106.53% 210.83% -50.94%
% of Gross Profit 56.56% 128.94% 45.46%
Depreciation & Amortization $3.858M $3.856M $3.626M
YoY Change -3.07% 6.34% -5.45%
% of Gross Profit 16.59% 25.87% 26.66%
Operating Expenses $54.98M $56.90M $31.05M
YoY Change 70.08% 83.23% -27.77%
Operating Profit -$31.72M -$41.99M -$17.45M
YoY Change 49.81% 140.63% -54.75%
Interest Expense $3.941M $4.444M $1.129M
YoY Change 222.24% 293.62% -104.83%
% of Operating Profit
Other Income/Expense, Net $957.0K $412.0K $1.839M
YoY Change -33.91% -77.6% -156.79%
Pretax Income -$26.82M -$45.66M -$16.74M
YoY Change 28.04% 172.79% -74.31%
Income Tax $100.0K $55.00K $300.0K
% Of Pretax Income
Net Earnings -$26.94M -$45.72M -$17.04M
YoY Change 28.29% 168.3% -73.18%
Net Earnings / Revenue -59.9% -122.88% -61.59%
Basic Earnings Per Share -$0.07 -$0.12 -$0.22
Diluted Earnings Per Share -$0.07 -$0.12 -$0.22
COMMON SHARES
Basic Shares Outstanding 371.2M 372.1M 78.38M shares
Diluted Shares Outstanding 371.5M 372.3M 78.67M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $366.3M $394.7M $142.3M
YoY Change 184.31% 177.37% -32.62%
Cash & Equivalents $210.6M $269.8M $142.3M
Short-Term Investments $155.7M $124.9M $0.00
Other Short-Term Assets $9.316M $10.26M $3.567M
YoY Change 174.0% 187.55% -39.93%
Inventory $42.64M $42.62M $22.08M
Prepaid Expenses
Receivables $35.32M $32.44M $15.12M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $453.6M $480.0M $183.1M
YoY Change 165.67% 162.21% -27.03%
LONG-TERM ASSETS
Property, Plant & Equipment $41.98M $74.10M $24.52M
YoY Change 71.09% 202.18% -60.88%
Goodwill $106.3M $106.3M $106.3M
YoY Change 0.11% -0.03%
Intangibles $23.37M $24.08M $7.000M
YoY Change 456.36% 243.97%
Long-Term Investments
YoY Change
Other Assets $4.640M $20.53M $2.754M
YoY Change 94.14% 645.61% 22.89%
Total Long-Term Assets $227.9M $228.7M $172.8M
YoY Change 35.24% 32.38% -9.19%
TOTAL ASSETS
Total Short-Term Assets $453.6M $480.0M $183.1M
Total Long-Term Assets $227.9M $228.7M $172.8M
Total Assets $681.5M $708.7M $355.8M
YoY Change 100.88% 99.18% -19.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.93M $12.57M $6.089M
YoY Change 49.12% 106.44% -32.46%
Accrued Expenses $31.69M $37.78M $7.176M
YoY Change 210.68% 426.48% -61.45%
Deferred Revenue $13.44M $15.11M $11.69M
YoY Change 19.6% 29.34%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $54.91M $54.78M $4.583M
YoY Change 998.26% 1095.35%
Total Short-Term Liabilities $120.6M $123.8M $46.84M
YoY Change 132.85% 164.32% 9.52%
LONG-TERM LIABILITIES
Long-Term Debt $299.0K $299.0K $60.66M
YoY Change -99.5% -99.51% -6.02%
Other Long-Term Liabilities $1.510M $73.52M $843.0K
YoY Change 39.04% 8621.59% -98.56%
Total Long-Term Liabilities $1.510M $73.82M $843.0K
YoY Change 39.04% 8657.06% -99.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $120.6M $123.8M $46.84M
Total Long-Term Liabilities $1.510M $73.82M $843.0K
Total Liabilities $192.2M $198.5M $158.0M
YoY Change 20.32% 25.65% -5.6%
SHAREHOLDERS EQUITY
Retained Earnings -$1.152B -$1.125B -$960.0M
YoY Change 17.39% 17.15%
Common Stock $390.0K $389.0K $81.00K
YoY Change 375.61% 380.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $489.3M $510.3M -$113.4M
YoY Change
Total Liabilities & Shareholders Equity $681.5M $708.7M $355.8M
YoY Change 100.88% 99.18% -19.34%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$26.94M -$45.72M -$17.04M
YoY Change 28.29% 168.3% -73.18%
Depreciation, Depletion And Amortization $3.858M $3.856M $3.626M
YoY Change -3.07% 6.34% -5.45%
Cash From Operating Activities -$27.87M -$39.05M -$9.329M
YoY Change 144.04% 318.59% -68.89%
INVESTING ACTIVITIES
Capital Expenditures $2.255M $1.937M $838.0K
YoY Change 150.56% 131.15% -189.34%
Acquisitions
YoY Change
Other Investing Activities -$28.63M $52.19M $40.96M
YoY Change -41.6% 27.41% -129.83%
Cash From Investing Activities -$30.88M $50.26M $40.13M
YoY Change -38.15% 25.25% -129.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.000K -28.36M -2.084M
YoY Change -99.83% 1260.89% -100.98%
NET CHANGE
Cash From Operating Activities -27.87M -39.05M -9.329M
Cash From Investing Activities -30.88M 50.26M 40.13M
Cash From Financing Activities -2.000K -28.36M -2.084M
Net Change In Cash -58.75M -17.15M 28.71M
YoY Change -6.02% -159.75% -35.81%
FREE CASH FLOW
Cash From Operating Activities -$27.87M -$39.05M -$9.329M
Capital Expenditures $2.255M $1.937M $838.0K
Free Cash Flow -$30.12M -$40.99M -$10.17M
YoY Change 144.51% 303.14% -65.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001162194
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34180
dei Entity Registrant Name
EntityRegistrantName
STANDARD BIOTOOLS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0513190
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Tower Place
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2000
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
266-6000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
LAB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
371154471
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
269811000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51704000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
124902000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
63191000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32441000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19660000
CY2024Q2 us-gaap Inventory Net
InventoryNet
42618000
CY2023Q4 us-gaap Inventory Net
InventoryNet
20533000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10257000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3127000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
480029000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
158215000
CY2024Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
16252000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
0
CY2024Q2 lab Royalty Receivable Non Current
RoyaltyReceivableNonCurrent
3738000
CY2023Q4 lab Royalty Receivable Non Current
RoyaltyReceivableNonCurrent
0
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42569000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24187000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31531000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30663000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4282000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2285000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24078000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1400000
CY2024Q2 us-gaap Goodwill
Goodwill
106253000
CY2023Q4 us-gaap Goodwill
Goodwill
106317000
CY2024Q2 us-gaap Assets
Assets
708732000
CY2023Q4 us-gaap Assets
Assets
323067000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12570000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9236000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31929000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21019000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5851000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4323000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15113000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11607000
CY2024Q2 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3562000
CY2023Q4 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3612000
CY2024Q2 us-gaap Secured Debt Current
SecuredDebtCurrent
0
CY2023Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
5000000
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
54783000
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
54530000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
123808000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
109327000
CY2024Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
299000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
569000
CY2024Q2 us-gaap Secured Long Term Debt
SecuredLongTermDebt
0
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
3414000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
841000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
841000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29617000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30374000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
33395000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3520000
CY2024Q2 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
8995000
CY2023Q4 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
10755000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1516000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1065000
CY2024Q2 us-gaap Liabilities
Liabilities
198471000
CY2023Q4 us-gaap Liabilities
Liabilities
159865000
CY2024Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2024Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
256000
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
256000
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
256000
CY2024Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2023Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
255559000
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
311253000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9744000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
389703000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83364000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
371123000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80232000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
389000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
83000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1682480000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
860816000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1500000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2221000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1124641000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1000752000
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
18580000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3132000
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
46467000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5977000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
510261000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-148051000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
708732000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
323067000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37205000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27666000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
82745000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52785000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
22297000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14064000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
43649000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26902000
CY2024Q2 us-gaap Gross Profit
GrossProfit
14908000
CY2023Q2 us-gaap Gross Profit
GrossProfit
13602000
us-gaap Gross Profit
GrossProfit
39096000
us-gaap Gross Profit
GrossProfit
25883000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19222000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6184000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35202000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12613000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37674000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22600000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
84617000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
43895000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
5749000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
2267000
us-gaap Restructuring Charges
RestructuringCharges
10033000
us-gaap Restructuring Charges
RestructuringCharges
3417000
CY2024Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2782000
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
19945000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
65427000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
31051000
us-gaap Operating Expenses
OperatingExpenses
149797000
us-gaap Operating Expenses
OperatingExpenses
59925000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-50519000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17449000
us-gaap Operating Income Loss
OperatingIncomeLoss
-110701000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34042000
CY2024Q2 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
CY2023Q2 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
25213000
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
CY2024Q2 us-gaap Interest Income Operating
InterestIncomeOperating
4444000
CY2023Q2 us-gaap Interest Income Operating
InterestIncomeOperating
244000
us-gaap Interest Income Operating
InterestIncomeOperating
9618000
us-gaap Interest Income Operating
InterestIncomeOperating
316000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
412000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
466000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1822000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
407000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45663000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16739000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-77692000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33319000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
55000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
301000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
183000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
564000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-45718000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17040000
us-gaap Net Income Loss
NetIncomeLoss
-77875000
us-gaap Net Income Loss
NetIncomeLoss
-33883000
CY2024Q2 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
0
CY2023Q2 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
0
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
46014000
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
0
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-45718000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17040000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-123889000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33883000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
372331000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
372331000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78669000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78669000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
333228000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
333228000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78873000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78873000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-45718000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17040000
us-gaap Net Income Loss
NetIncomeLoss
-77875000
us-gaap Net Income Loss
NetIncomeLoss
-33883000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
308000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-327000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
844000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-157000
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-16000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
104000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-123000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
502000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
292000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-223000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
721000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
345000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45426000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17263000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77154000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33538000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-148051000
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
311253000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-18000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
72000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11611000
CY2024Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11051000
CY2024Q1 lab Common Stock Relinquished In Litigation Settlement
CommonStockRelinquishedInLitigationSettlement
1009000
CY2024Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
444219000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-32157000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
429000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
577316000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-326000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
425000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
981000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6730000
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
29439000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-45718000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
292000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
510261000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-81467000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-93000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3148000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2466000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16843000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
568000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-97153000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-36000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
326000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3114000
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2375000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17040000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-223000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-113387000
us-gaap Net Income Loss
NetIncomeLoss
-77875000
us-gaap Net Income Loss
NetIncomeLoss
-33883000
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
25213000
us-gaap Share Based Compensation
ShareBasedCompensation
18341000
us-gaap Share Based Compensation
ShareBasedCompensation
6262000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2822000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5600000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
6228000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
1688000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4544000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
151000
lab Non Cash Lease Expense
NonCashLeaseExpense
2949000
lab Non Cash Lease Expense
NonCashLeaseExpense
1902000
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
1874000
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
572000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-453000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
868000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
327000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5012000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2238000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12777000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1939000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3291000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-426000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10694000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1774000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3860000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
659000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1207000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
937000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2984000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1836000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4442000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1158000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-101526000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17814000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
280033000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
147984000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
6836000
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
239000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
91964000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2718000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1848000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
368331000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
83280000
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
8192000
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
545000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
40490000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4841000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
425000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
326000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
344000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
127000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1052000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-48094000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4642000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-110000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-49000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
218601000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
60775000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52499000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82324000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
271100000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143099000
lab Equity Consideration Transferred In Connection With Merger
EquityConsiderationTransferredInConnectionWithMerger
444219000
us-gaap Interest Paid Net
InterestPaidNet
1640000
us-gaap Interest Paid Net
InterestPaidNet
1919000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
347000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
512000
lab Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
91000
lab Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
211000
lab Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
761000
lab Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
740000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosed in the accompanying notes. Actual results could differ materially from these estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates and assumptions which form the basis of amounts reported in the condensed consolidated financial statements include, but are not limited to, the identification of performance obligations in contracts with customers; standalone selling prices of the Company's performance obligations; timing of revenue recognition; fair value measurements; net realizable value of inventory; income taxes; and the fair value of intangible assets acquired in business combinations. The Company bases its estimates on current facts and circumstances, historical experience, forecasted results, and various other assumptions that it believes to be reasonable. The Company obtains reports from third-party valuation experts to inform and support estimates related to certain fair value measurements.</span></p>
lab Amortizes Internal Use Software Costs Using Straight Line Method
AmortizesInternalUseSoftwareCostsUsingStraightLineMethod
P3Y
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q2 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
48134000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
83390000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
93632000
CY2023Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-39557000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-107693000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-67796000
us-gaap Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
38600000
us-gaap Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
29000000
CY2024Q2 us-gaap Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
14700000
CY2024Q2 us-gaap Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
13700000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37205000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27666000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
82745000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52785000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37205000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27666000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
82745000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52785000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
15127000
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
34189000
lab Contract With Customer Revenue Recognized
ContractWithCustomerRevenueRecognized
-9746000
lab Contract With Customer Revenue Recognized Net
ContractWithCustomerRevenueRecognizedNet
8938000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
48508000
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
8099000
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
7714000
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
3304000
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1458000
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
20575000
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
142699000
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
118621000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
24078000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
117354000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
115954000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1400000
CY2024Q2 lab Amortization Of Acquired Intangible Assets
AmortizationOfAcquiredIntangibleAssets
700000
CY2023Q2 lab Amortization Of Acquired Intangible Assets
AmortizationOfAcquiredIntangibleAssets
2800000
lab Amortization Of Acquired Intangible Assets
AmortizationOfAcquiredIntangibleAssets
2800000
lab Amortization Of Acquired Intangible Assets
AmortizationOfAcquiredIntangibleAssets
5600000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1423000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2844000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2844000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2844000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2844000
CY2024Q2 lab Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
11279000
CY2024Q2 lab Finite Lived Intangible Assets Future Expected Amortization Expense
FiniteLivedIntangibleAssetsFutureExpectedAmortizationExpense
24078000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
269811000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51704000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1289000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
795000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
271100000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52499000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1300000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
800000
CY2024Q2 lab Trade Receivables
TradeReceivables
28103000
CY2023Q4 lab Trade Receivables
TradeReceivables
19972000
CY2024Q2 lab Royalty Receivable Current
RoyaltyReceivableCurrent
4814000
CY2023Q4 lab Royalty Receivable Current
RoyaltyReceivableCurrent
0
CY2024Q2 lab Allowance For Expected Credit Losses
AllowanceForExpectedCreditLosses
-476000
CY2023Q4 lab Allowance For Expected Credit Losses
AllowanceForExpectedCreditLosses
-312000
CY2024Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
32441000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
19660000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
49260000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
12140000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
625000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
282000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8985000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8111000
CY2024Q2 us-gaap Inventory Gross
InventoryGross
58870000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
20533000
CY2024Q2 lab Inventory Current
InventoryCurrent
42618000
CY2023Q4 lab Inventory Current
InventoryCurrent
20533000
CY2024Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
16252000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
0
CY2024Q2 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
1200000
CY2023Q2 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
200000
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
1900000
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
600000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
103790000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
57342000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
66566000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35489000
CY2024Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
5345000
CY2023Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2334000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42569000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24187000
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3100000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1700000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14004000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12052000
CY2024Q2 lab Loss Contingency Accruals
LossContingencyAccruals
3297000
CY2023Q4 lab Loss Contingency Accruals
LossContingencyAccruals
0
CY2024Q2 lab Accrued Warranties Current
AccruedWarrantiesCurrent
2876000
CY2023Q4 lab Accrued Warranties Current
AccruedWarrantiesCurrent
2593000
CY2024Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
3743000
CY2023Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
825000
CY2024Q2 lab Accrued Uninvoiced Receipts Current
AccruedUninvoicedReceiptsCurrent
1037000
CY2023Q4 lab Accrued Uninvoiced Receipts Current
AccruedUninvoicedReceiptsCurrent
1516000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6972000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4033000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31929000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21019000
CY2020Q3 lab Research And Development Arrangement Contract To Perform For Others Maximum Contract Value
ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue
34000000
CY2020Q3 lab Research And Development Arrangement Contract To Perform For Others Capital Expenditures
ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures
22200000
CY2023Q2 lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
900000
CY2024Q2 lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
900000
lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
1800000
lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
1800000
CY2024Q2 lab Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses
9600000
CY2023Q4 lab Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses
7800000
CY2024Q2 lab Research And Development Arrangement Contract To Perform For Others Property And Equipment Net
ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet
12600000
CY2023Q4 lab Research And Development Arrangement Contract To Perform For Others Property And Equipment Net
ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet
14400000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
55082000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
63513000
lab Number Of Leases For Office And Laboratory Space
NumberOfLeasesForOfficeAndLaboratorySpace
3
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
extend the leases
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
2542000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
2001000
us-gaap Operating Lease Cost
OperatingLeaseCost
5098000
us-gaap Operating Lease Cost
OperatingLeaseCost
4011000
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1398000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
822000
us-gaap Variable Lease Cost
VariableLeaseCost
2593000
us-gaap Variable Lease Cost
VariableLeaseCost
1587000
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
1076000
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
528000
us-gaap Sublease Income
SubleaseIncome
2152000
us-gaap Sublease Income
SubleaseIncome
1449000
CY2024Q2 us-gaap Lease Cost
LeaseCost
2864000
CY2023Q2 us-gaap Lease Cost
LeaseCost
2295000
us-gaap Lease Cost
LeaseCost
5539000
us-gaap Lease Cost
LeaseCost
4149000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4797000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9703000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8747000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7400000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7355000
CY2024Q2 lab Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
10224000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48226000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12758000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
35468000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5851000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29617000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.119
CY2024Q2 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
18500000
CY2024Q1 lab Settled Outstanding Litigation
SettledOutstandingLitigation
422048
CY2024Q2 lab Settlement Of Outstanding Litigation
SettlementOfOutstandingLitigation
6200000
CY2024Q2 lab Repurchase Of Common Stock Shares For Litigation Settlement
RepurchaseOfCommonStockSharesForLitigationSettlement
1840000
CY2024Q2 us-gaap Share Price
SharePrice
2.4
CY2024Q2 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
1800000
us-gaap Litigation Settlement Loss
LitigationSettlementLoss
600000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
158654000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
158607000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
98554000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
98576000
CY2024Q2 us-gaap Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss
DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery
DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery
0
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
906
lab Change In Fair Value Of Warrant Liabilities Recurring Basis
ChangeInFairValueOfWarrantLiabilitiesRecurringBasis
453
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
453
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
30070000
lab Stock Based Compensation Expense Due To Acceleration Of Awards
StockBasedCompensationExpenseDueToAccelerationOfAwards
6200000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9294
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.62
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
lab Stock Options Assumed Through Acquisition
StockOptionsAssumedThroughAcquisition
28184
lab Stock Options Assumed Weighted Average Exercise Price
StockOptionsAssumedWeightedAverageExercisePrice
4.8
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
6697
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.5
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
531
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1338
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.44
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
42306
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
26938
CY2024Q2 lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
4.88
lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne
P5Y
CY2024Q2 lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue
6
lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
15368
CY2024Q2 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
3.09
lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1
P9Y
CY2024Q2 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
3
CY2024Q2 us-gaap Share Price
SharePrice
1.77
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6730000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3114000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18341000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6262000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-45718000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17040000
us-gaap Net Income Loss
NetIncomeLoss
-77875000
us-gaap Net Income Loss
NetIncomeLoss
-33883000
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
46014000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-45718000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17040000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-123889000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33883000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
372331000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
372331000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78669000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78669000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
333228000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
333228000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78873000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78873000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
53275000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14366000
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
75164000
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
11692000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
83938000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
108506000
CY2024Q2 lab Number Of Additional Shares Issuable Under Make Whole Premium Maximum
NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum
4741374
CY2024Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
11329047
CY2023Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1208200
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
15448533
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
2458684
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37205000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27666000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
82745000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52785000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
5749000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
2267000
us-gaap Restructuring Charges
RestructuringCharges
10033000
us-gaap Restructuring Charges
RestructuringCharges
3417000
CY2024Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2782000
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
19945000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-50519000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17449000
us-gaap Operating Income Loss
OperatingIncomeLoss
-110701000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34042000
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3856000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3626000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9050000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7288000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
5700000
us-gaap Restructuring Charges
RestructuringCharges
10000000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
2300000
us-gaap Restructuring Charges
RestructuringCharges
3400000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
825000
us-gaap Restructuring Charges
RestructuringCharges
10033000
us-gaap Payments For Restructuring
PaymentsForRestructuring
7115000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
3743000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
2267000
us-gaap Restructuring Charges
RestructuringCharges
10033000
us-gaap Restructuring Charges
RestructuringCharges
3417000
CY2024Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
46465458
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 lab Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q2 lab Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-091888-index-headers.html Edgar Link pending
0000950170-24-091888-index.html Edgar Link pending
0000950170-24-091888.txt Edgar Link pending
0000950170-24-091888-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img187295779_0.jpg Edgar Link pending
lab-20240630.htm Edgar Link pending
lab-20240630.xsd Edgar Link pending
lab-ex10_2.htm Edgar Link pending
lab-ex31_1.htm Edgar Link pending
lab-ex31_2.htm Edgar Link pending
lab-ex32_1.htm Edgar Link pending
lab-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lab-20240630_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending